No thanks—NMTI ceased being a value stock a long time ago. Before today’s news, it was up 300% from where I bought it a year ago (#msg-5041574), thanks in part to Cramer’s pumping.
It’s down about 30% today after missing the primary endpoint in the MIST trial, although there was an efficacy signal.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”